View source for Naftidrofuryl

{{drugbox |
| IUPAC_name        = 2-diethylaminoethyl 2-(naphthalen-1-ylmethyl)-<br>3-(oxolan-2-yl)propanoate
| image             = Naftidrofuryl.png
| CAS_number        = 31329-57-4
| ATC_prefix        = C04
| ATC_suffix        = AX21
| PubChem           = 4417
| DrugBank          = 
| C = 24 | H = 33 | N = 1 | O = 3
| molecular_weight  = 383.524 g/mol
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}
__NOTOC__
{{SI}}
{{CMG}}

==Overview==

'''Naftidrofuryl''' ([[International Nonproprietary Name|INN]], also known as '''nafronyl''' or as the [[oxalate]] salt '''naftidrofuryl oxalate''' or '''nafronyl oxalate''') is a drug used in the management of peripheral and [[Cerebrum|cerebral]] [[Blood vessel|vascular]] disorders. It is claimed to enhance cellular oxidative capacity and to be a [[muscle relaxant#Spasmolytics|spasmolytic]].<ref>{{cite book |author=Reynolds, J.E.F. (ed.)|title=[[Martindale: The complete drug reference|Martindale: The extra pharmacopoeia]] |publisher=Pharmaceutical Press |location=London |year=1993 |edition=30th edition |isbn=0-85369-300-5 |page=1310}}</ref> It may also be a  [[5-HT receptor|5-HT<sub>2</sub> receptor]] [[receptor antagonist|antagonist]]. It is also licenced for the treatment of [[intermittent claudication]] due to peripheral arterial disease.

It is sold under the brand name [[Dusodril]] ([[Merck & Co.|Merck]]) and cerebromap for multiapex in middle east. It is also sold as Praxilene in the United Kingdom.<ref>http://www.patient.co.uk/medicine/naftidrofuryl</ref>

Historically, it has been used to treat sudden [[idiopathic]] hearing loss and acute [[tinnitus]].<ref>http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm</ref>

Naftidrofuryl may be effective for relieving the pain of muscle [[cramp]]s.<ref name=Katzberg>{{cite journal |author=Katzberg HD, Khan AH, So YT |title=Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |journal=Neurology |volume=74 |issue=8 |pages=691–6 |date=February 2010 |pmid=20177124 |doi=10.1212/WNL.0b013e3181d0ccca |url=}}</ref>

==References==
{{reflist|2}}

{{Peripheral vasodilators}}

[[Category:Vasodilators]]
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]